Atenolol Global Market Report 2024

Atenolol belongs to the beta-blocker class of medications, primarily used to treat cardiovascular conditions. It's commonly prescribed for managing hypertension, angina, and preventing heart attacks. Atenolol is administered orally in tablet form, known for its efficacy in regulating heart function and lowering blood pressure.

The main types of atenolol are categorized based on purity, typically 98% and 99%. Purity percentage indicates the substance's freedom from impurities. Atenolol is available in various forms such as tablets and IV solutions, distributed through channels such as hospital pharmacies, drug stores, and online platforms. It is utilized for treating conditions such as hypertension, angina, arrhythmia, among others.

The atenolol market research report is one of a series of new reports that provides atenolol market statistics, including atenolol industry global market size, regional shares, competitors with an atenolol market share, detailed atenolol market segments, market trends, and opportunities, and any further data you may need to thrive in the atenolol industry. This atenolol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atenolol market size has grown strongly in recent years. It will grow from $11.05 billion in 2023 to $12.01 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth observed in the historic period can be attributed to several factors, including increased demand and consumption of antihypertensive drugs, a larger patient pool with conditions such as arrhythmia and angina, a rise in the prevalence of glaucoma and arrhythmia, and an increase in the popularity of online pharmacies.

The atenolol market size is expected to see strong growth in the next few years. It will grow to $15.85 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The expected growth in the forecast period can be attributed to several factors, including the increasing demand for atenolol, a growing prevalence of hypertension, heightened awareness of the complexities related to hypertension, a significant rise in the aging population, and poor lifestyle and dietary habits leading to cardiovascular issues. Major trends anticipated during this period include a demand for beta blockers, specifically beta-1 selective blockers, recent regulatory approvals for new formulations, the development of extended-release formulations, and a rising demand for combination therapies in treating cardiovascular conditions.

The atenolol market is poised for growth driven by the increasing prevalence of cardiovascular diseases (CVDs). CVDs encompass a range of disorders affecting the heart and blood vessels and are on the rise due to factors such as population growth, aging demographics, various risk factors, and gaps in implementing proven prevention and treatment strategies. Atenolol plays a pivotal role in managing CVDs by reducing heart rate, lowering blood pressure, alleviating angina symptoms, preventing heart attacks, and managing arrhythmias. Its ability to stabilize heart function, control blood pressure, and prevent complications contributes significantly to long-term cardiovascular health. For example, the Centers for Disease Control and Prevention reported that the prevalence of coronary heart disease among adults aged 18 and over slightly increased from 4.6% in 2020 to 4.9% in 2021, highlighting the impact of growing CVD prevalence on the atenolol market.

The rising prevalence of hypertension, also known as high blood pressure, is expected to drive the growth of the atenolol market. Hypertension is characterized by consistently elevated blood pressure against arterial walls and is influenced by lifestyle choices, dietary habits, stress levels, and demographic shifts. Atenolol helps manage hypertension by reducing heart rate, diminishing the force of heart contractions, and inhibiting the renin-angiotensin-aldosterone system, collectively lowering blood pressure and mitigating hypertension-related complications. According to the World Health Organization, an estimated 1.28 billion adults aged 30-79 worldwide have hypertension, underscoring the role of hypertension prevalence in propelling the atenolol market.

In April 2023, Marksans Pharma completed the acquisition of Teva Pharmaceutical Industries, aiming to expand its manufacturing capacity in India and diversify its product portfolio. Teva Pharmaceutical Industries, based in Israel, is a key manufacturer of atenolol.

Major companies operating in the atenolol market are F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories Inc., Shanghai Pharmaceuticals Holding Co. Ltd., LGM Pharma, Torrent Pharmaceuticals GmbH, Cipla Inc., Intas Pharmaceuticals Limited, Lupin Limited, Macleods Pharmaceuticals Ltd., Ipca Laboratories Limited, Aristo Pharmaceuticals Pvt. Ltd, Medley Pharmaceuticals Ltd., Micro Labs Ltd., Unichem Laboratories Limited, Harman Finochem Ltd., Axplora, Erregierre SpA, Darou Pakhsh Pharma Chem Co., Zydus Pharmaceuticals (USA) Inc., Anant Pharmaceuticals Pvt. Ltd., Enomark LLC, Hairui Chemical, Octavius Pharma Pvt. Ltd., Hoventa Pharma.

North America was the largest region in the atenolol market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atenolol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atenolol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atenolol market consists of sales of atenolol tablets, atenolol injections, fixed-dose combinations, and distribution channels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.